Persistence of Tofacitinib in the Treatment of Rheumatoid Arthritis in Open-Label, Long-Term Extension Studies up to 9.5 Years.
Janet E PopeEdward KeystoneShahin JamalLisy WangLara FallonJohn WoolcottIrina LazariciuDouglass ChapmanBoulos HaraouiPublished in: ACR open rheumatology (2019)
Median drug survival of tofacitinib-treated patients participating in LTE studies was approximately 5 years and was similar for tofacitinib dosed at 5 and 10 mg BID. Reduced drug survival was associated with negative anti-CCP/RF status, TNFi-IR, and certain comorbidities. These data support tofacitinib use for long-term management of RA.
Keyphrases
- rheumatoid arthritis
- disease activity
- open label
- newly diagnosed
- ankylosing spondylitis
- interstitial lung disease
- end stage renal disease
- ulcerative colitis
- clinical trial
- case control
- electronic health record
- squamous cell carcinoma
- drug induced
- systemic lupus erythematosus
- big data
- radiation therapy
- machine learning
- data analysis
- patient reported
- combination therapy